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S U M M A R Y
Objectives: We present a case of bilateral polymicrobial osteomyelitis with Candida tropicalis and Candida
krusei, and review the literature on Candida osteomyelitis.
Methods: PubMed was searched for cases of Candida osteomyelitis published in the English-language
literature between 1970 and 2010.
Case: A 60-year-old previously healthy man was hospitalized with gallstone pancreatitis. Between 3
weeks and 6 months after hospitalization, he developed bilateral osteomyelitis of the feet with C.
tropicalis and C. krusei. The patient was treated with surgery, ﬂuconazole, and a liposomal formulation of
amphotericin B. The left lower limb was amputated, and at a 2-year follow-up, the patient had almost no
pain in his right foot.
Literature review: We identiﬁed 40 new cases in the literature since the latest review in 2004. Most cases
of Candida osteomyelitis are caused by Candida albicans, but an increasing number are caused by non-
albicans species. The prognosis is favorable, with full recovery in the majority of cases.
Conclusions: Candida osteomyelitis should be considered when a patient presents with risk factors and
pain without previous trauma, because Candida, despite being part of the normal ﬂora, is the fourth
leading cause of hematogenous nosocomial infections. The recommended treatment is surgery and
ﬂuconazole as monotherapy or initially combined with a fungicidal agent, either a different
amphotericin B formulation or an echinocandin.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Osteomyelitis occurs acutely or chronically and may be caused
by hematogenous spread or direct inoculation.1,2 The infection can
be caused by a low pathogenic microorganism, and the clinical
symptoms may be sparse, making early diagnosis difﬁcult.3,4
Osteomyelitis caused by Candida is rare. However, an increase in
predisposing risk factors, such as broad-spectrum antibiotics,
central venous catheters (CVC), parenteral nutrition, and immu-
nosuppression have been identiﬁed in recent decades, and more
cases are expected.3,5,6 Arias reviewed 110 case reports of Candida
osteomyelitis published between 1970 and 2002.5 The most
frequent localizations were the vertebra (40%) and sternum (8%).
The most common associated species was Candida albicans,
followed by Candida tropicalis and Candida glabrata. To our
knowledge, six cases have been described in which polymicrobial* Corresponding author. Tel.: +45 27143406; fax: +45 38261235.
E-mail address: nckaldau@gmail.com (N.C. Kaldau).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.10.001osteomyelitis was caused by two or more species of Candida.7–12
We identiﬁed only two cases of Candida krusei osteomyelitis.7,13
We present a case in which a previously healthy patient with
gallstone pancreatitis developed bilateral polymicrobial osteomy-
elitis of the feet caused by C. tropicalis, C. krusei, and Eikenella
corrodens. We further review and update the English-language
literature of cases of Candida osteomyelitis.
2. Methods
We conducted a PubMed search of the English-language
literature published between 1970 and 2010, applying the
following free-text words: osteomyelitis, osteitis, Candida,
multifocal, polymicrobial, and multi-species. Subsequently,
Candida was individually combined with the free-text words
using ‘AND’. We further reassessed all cases included in the review
by Arias et al.5 covering the period from 1970 to 2002 and
reviewed all identiﬁed articles presented in that review.
Furthermore, all identiﬁed reported cases of microbiologically
veriﬁed Candida osteomyelitis from the period 2002 to 2010 were
reviewed.ses. Published by Elsevier Ltd. All rights reserved.
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A healthy 60-year-old man was hospitalized in February 2007
(day 1) with gallstone pancreatitis and was prescribed penicillin
(2 000 000 IU  3 intravenous (IV)), metronidazole (500 mg  3
IV), and gentamicin (240 mg  1 IV). On day 2, the antibiotics were
replaced with cefuroxime (1.5 g  3 IV).
On day 21, the patient developed pain in his left ankle, bilateral
swelling of his feet and ankles, and leukocytoclastic vasculitis,
veriﬁed by a punch biopsy. The patient was prescribed oral
prednisolone (25 mg/day), which diminished the skin lesions.
Cefuroxime was suspected to be the cause of the vasculitis and was
replaced by the same antibiotics as above. However, the patient’s
ankle pain remained unchanged.
On day 34, blood cultures tested positive for non-albicans
Candida, and ﬂuconazole (400 mg/day IV) and voriconazole
(320 mg/day IV) were prescribed. On day 41, cultures revealed
C. tropicalis, and the azoles were substituted by a liposomal
formulation of amphotericin B (LF AmB) for 14 days (160 mg  1
IV). The minimum inhibitory concentration (MIC; by E-test) was
2.0 mg/ml for ﬂuconazole and 0.5 mg/ml for amphotericin B. There
were no signs of ocular candidiasis or endocarditis. A continually
elevated C-reactive protein (CRP) of 168 mg/l and a white blood
cell count (WBC) of 17  109/l on day 48 led to the puncture of a
pancreatic cyst; the culture tested positive for C. tropicalis.
The patient’s clinical condition normalized, and on day 55 he
was discharged with decreasing swelling and pain in his left ankle.
On day 72, the patient was readmitted to the hospital with
symptoms and clinical signs of septic arthritis in the left ankle joint
and pus exuding from the left heel. From days 72 to 91, the
patient’s left ankle was treated surgically three times. The ﬁrst
time, an arthroscopic synovectomy was also performed. None of
the surgeons found any evidence of osteomyelitis. The patient was
treated with vancomycin IV and dicloxacillin IV based on tissue
culture results that were positive for streptococci, Staphylococcus
aureus, and coagulase-negative staphylococci. X-rays showed no
evidence of osteomyelitis, but the patient still had an elevated CRP
of 86 mg/l and a WBC count of 12  109/l.
On day 112, a leukocyte scan revealed increased uptake in the
left calcaneus stretching up the back of the lower leg, a small
increase in uptake in the right tuber calcaneus, and a smaller
charge proximally around the triceps surae muscle.
On day 125, a surgical revision of the left ankle was performed.
Necrotic soft tissue was removed, but no signs of bone or joint
involvement were found. On day 138, a surgical revision of the left
ankle revealed a necrotic calcaneus. The talus was partially
corroded. The right foot was not revised because there were no
symptoms or objective ﬁndings. Based on the tissue culture from
the calcaneus, which was positive for E. corrodens, the patient
received penicillin (2 000 000 IU  4 IV). On day 149, another
surgical revision was performed. Tissue culture from the necrotic
calcaneus tested positive for C. tropicalis. The MICs for C. tropicalis
were determined to be 0.5 mg/ml for ﬂuconazole and 0.25 mg/ml
for AmB. Fluconazole (400 mg/day IV) was instituted.
On day 163, the patient had a high crural amputation. On day
178, after 14 days of ﬂuconazole treatment and 35 days of
penicillin treatment, the antibiotics were discontinued because the
cultures were negative, and the patient was discharged for
outpatient monitoring.
Six months after the primary gallstone pancreatitis, on day 185,
the patient had pain and a purulent discharge from the right heel
and was readmitted to hospital. A surgical revision of the heel
revealed an abscess and a necrotic calcaneus. The patient was
administered cefuroxime (1.5 g  3 IV). On day 189, the samples
from the calcaneus tested positive for Candida. Cefuroxime was
substituted by ﬂuconazole (400 mg  1 IV) for 14 days until day203, when the ﬁnal culture was positive for C. krusei and C.
tropicalis, and the patient received LF AmB (180 mg  1 IV). The
MICs for C. krusei were determined to be 256 mg/ml for ﬂuconazole
and 0.004 mg/ml for AmB. The MICs for C. tropicalis were
determined to be 1.0 mg/ml for ﬂuconazole and 0.047 mg/ml for
AmB.
On day 271, a magnetic resonance imaging (MRI) scan showed
osteomyelitis of the calcaneus, talus, distal ﬁbula, medial cunei-
form bone, and metatarsals I, III, IV, and V. On day 277, a follow-up
biopsy of the calcaneus tested positive for coagulase-negative
staphylococci, but not for Candida; therefore, rifampin
(300 mg  2 IV) and fusidic acid (500 mg  3 IV) were initiated.
On day 320, after 4 months of treatment with LF AmB, the
patient was discharged to outpatient monitoring. On discharge, the
CRP was 34 mg/l and the WBC count was 11  109/l.
The 6-month control leukocyte scan continued to show a
slightly increased uptake in the right calcaneus, but no clinical
signs of infection. At 12 months and 24 months, the follow-up MRIs
showed unchanged conditions. The patient had no objective signs
of infection and almost no pain.
4. Literature review
From the literature published between 2002 and 2010, we
identiﬁed 40 new cases in addition to the case described above
(Table 1).1,5,13–39 A total of 21 cases (51%) were caused by C.
albicans and 14 (34%) by non-albicans species, including C.
tropicalis, Candida parapsilosis, Candida dubliniensis, C. krusei, and
C. glabrata. Eleven of the 41 patients were female, and four of the
patients were children. Of the known predisposing risk factors,
previous or current antibiotic usage was the most common.
Additional risk factors were diabetes, CVCs, previous surgery, IV
drug abuse, and general immunosuppression. The most frequent
localization was the spine (27 cases; 66%). Other locations included
the tibia, femur, sacrum, costae, metatarsals, talus, calcaneus, and
humerus. Seven patients had current or previous candidemia. The
predominant symptom was persistent pain. In some cases, the
patients had a fever. Treatment included a combination of surgery
and pharmacological treatment. In 11 cases, the treatment was
solely pharmacological. The treatment period varied from 14 days
preoperatively to lifelong therapy in one case. Fluconazole was the
most common agent used. Treatment with caspofungin and LF
AmB were used to good effect. There were only two reported cases
of adverse reactions to treatment; in one case this resulted in the
treatment being switched from amphotericin B deoxycholate and
AmB to LF AmB because of elevated transaminases and nephro-
toxicity. In 80% (33 patients) of the cases, there was full recovery,
with three patients having complete clinical remission but with
sequelae visible by MRI. One patient died from lung cancer 1
month after the diagnosis of osteomyelitis, and another patient
died 11 days after the diagnosis of osteomyelitis because of chronic
nephropathy. Three cases were reported but not described, and
three patients had less pain after treatment, but not complete
remission.
In Arias et al., 61 cases (58%) were caused by C. albicans, 17 (16%)
by C. tropicalis, and seven (7%) by C. glabrata (see Appendix).5 Other
species were Candida lusitaniae, Candida paratropicalis, Candida
pseudotropicalis, C. parapsilosis, Candida holmii, C. krusei, and Candida
guilliermondii. A total of 60 cases (57%) were localized to the spine.
The second most frequent localization was the sternum, in 21 (20%)
cases. Other localizations included the facial bones and long bones,
with a few cases in the bones of the foot and hand.
The treatment administered was ﬂuconazole, AmB, or a
combination. Ketoconazole, itraconazole, ﬂuconazole, and AmB
have each been combined with ﬂucytosine and miconazole have
been combined with AmB. A total of 66 patients (62%) made a
Table 1
Candida osteomyelitis cases reported between 2002 and 2010
Reference Species Location Sex/age Symptoms and signs;
blood culture
Risk factors Treatment Results/follow-up
Matta et al., 201014 C. albicans Sternum M/7 y Tumor, pruritus, purulent
discharge on second
admission
IV medication due to acute
demyelinating
encephalomyelitis
Initiation of ﬂuconazole, lost to
follow-up; relapse; surgery, ﬂuconazole
IV 6 weeks, PO 6 months
Resolved/12 months
Venditti 201015 NA Vertebra NA NA NA NA NA
Wellinghausen et al., 200916 C. dubliniensis Tibia, SI-joint, os
sacrum, vertebra
M/19 y Pain; BC negative Stem cell transplant Fluconazole 2 weeks; caspofungin
and AmB 3 months; voriconazole
IV 7 mg/kg and caspofungin
IV 50 mg/day 14 days; voriconazole PO
NA
Yener et al., 200917 C. albicans Metatarsal bone M/80 y Ulcers, pain DM Surgery and ﬂuconazole 400 mg/day
for 6 months
Clinically resolved, MRI
without improvement/
6 months
Metcalfe and
Morgan-Hough 200918
NA Vertebra NA Neck pain, strength
reduction, gait problems
AB, DM Surgery, LF AmB IV 4 weeks and
ﬂuconazole PO 17 months
Resolved/17 months
Bhogal et al., 200819 C. albicans Vertebra M/48 y Back pain; BC negative Mycotic AAA Surgery, ﬂuconazole 14 days; relapse
after 12 months, then ﬂuconazole 12 weeks
Resolved/24 months
Ozdemir et al., 200820 C. albicans Vertebra M/61 y Neck pain, strength
reduction in all extremities
Chronic renal failure,
hemodialysis, CVC
AmB 0.5 mg/kg/day Dead day 11
Cha et al., 200821 C. albicans Vertebra M/59 y Reduced mobility,
velopharyngeal insufﬁciency
Cured of nasopharyngeal
cancer, radiotherapy,
chemotherapy
NA NA
Schilling et al., 200813 C. krusei Vertebra M/58 y Back pain; BC positive AML, chemotherapy,
neutropenia, AB, LF AmB
prophylaxis
Surgery, caspofungin IV 50 mg/day 30 days
then 100 mg/day 7 months and posaconazole
PO 800 mg/day 12 months
Resolved/20 months
Ghersin et al., 200722 NA Vertebra M/72 y DM, previously C. albicans
endocarditis
Fluconazole 9 months; relapse of endocarditis
ﬂuconazole PO lifelong
Resolved
Sica et al., 200723 C. albicans Costa M/55 y Surgical site infection, sinus Surgery, esophageal
adenocarcinoma, steroid, AB
Surgery and ﬂuconazole PO 12 weeks Resolved/unreported
Sica et al., 200723 C. albicans Costa M/49 y Surgical site infection AB, surgery, gastrostomy Surgery and ﬂuconazole PO 10 weeks Resolved/unreported
Sica et al., 200723 C. albicans Costa M/48 y Abscess Surgery, gastric
carcinoma, AB
Surgery and ﬂuconazole PO 10 weeks Resolved/unreported
Sica et al., 200723 C. albicans Costa M/61 y Surgical site infection Surgery, radiotherapy,
esophageal tumor, AB
Surgery and ﬂuconazole PO 13 weeks Resolved/unreported
Cornely et al., 200724 NA NA NA NA NA Caspofungin 100 mg/day Favorable outcome/
3 months
Aryan et al., 200725 NA Vertebra M/61 y Myelopathy NA Surgery, AB (NA) lifelong Resolved/11–33 months
Legout et al., 200626 C. parapsilosis Humerus M/50 y Pain, ﬁstula IV drug abuse, HIV, hepatitis Surgery and voriconazole 400 mg/day 3 weeks;
side effects and relapse; surgery and
caspofungin 6 weeks
Resolved/11 months
Yang et al., 200627 C. tropicalis Costa, talus M/13 y Subfebrile, pain AML, BMT, candidemia Surgery and caspofungin IV 50 mg/day 40 days
and ﬂuconazole IV 600 mg/day 120 days,
PO 450 mg/day 60 days
Resolved/18 months
Khazim et al., 200628 C. albicans Vertebra F/70 y Neck pain, radiating pain;
BC negative
Non-immunocompromised Surgery, ﬂuconazole IV 400 mg/day 2 weeks,
PO 400 mg/day 10 weeks
Resolved/60 months
Khazim et al., 200628 C. albicans Vertebra M/65 y Back pain, weight loss,
malaise; BC negative
IDDM Surgery, ﬂuconazole 400 mg/day IV 2 weeks
preoperatively, 400 mg/day IV 2 weeks,
400 mg/day PO 12 weeks
Resolved/72 months
Khazim et al., 200628 C. albicans Vertebra F/31 y Back pain, radiating pain;
BC negative
Non-immunocompromised Surgery, ﬂuconazole 400 mg/day IV 2 weeks,
400 mg/day PO 10 weeks
Resolved/60 months
Pigrau et al., 200529 C. parapsilosis Vertebra NA NA NA Fluconazole PO 8 weeks; relapse; then
ﬂuconazole PO (time unreported)
Resolved/6 months
Pigrau et al., 200529 C. albicans Vertebra NA NA NA NA Resolved/6 months
Pigrau et al., 200529 C. albicans Vertebra NA NA NA NA Resolved/6 months
Gursel et al., 200530 NA Vertebra F/14 y Back pain; BC negative Factor X deﬁciency, IV
human coagulation factor II, VII,
IX and X due to menorrhagia
LF AmB 5 mg/kg/day IV 4 weeks, itraconazole
5 mg/kg/day PO 4 months
Resolved/12 months
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Table 1 (Continued )
Reference Species Location Sex/age Symptoms and signs;
blood culture
Risk factors Treatment Results/follow-up
Shaikh et al., 200531 C. tropicalis Vertebra F/68 y Back pain, fever;
BC positive
DM, CVC, surgery, AB Surgery, AmB 6 weeks and ﬂuconazole
6 months
Clinical improvement,
MRI status quo/6 months
Cone et al., 200532 C. albicans Vertebra M/NA Back pain Disseminated lung cancer,
candidemia earlier
LF AmB 6 weeks Pain resolved, MRI
improvement, died from
lung cancer 1 month later
Torres-Ramos et al., 200433 C. tropicalis Vertebra F/69 y Back pain Shoulder arthroplasty, AB,
cholestectomy
Surgery, AmB 12 weeks Resolved/12 months
Dogan et al., 20041 C. albicans Tibia F/5 m Wound infection;
BC negative
IO infusion, sepsis, AB Fluconazole 50 mg/day 4 weeks Resolved/12 months
Cone et al., 200434 C. parapsilosis Vertebra M/51 y Back pain Endocarditis (C. parapsilosis)
earlier, AmB, surgery
Surgery, AmB 1400 mg/day 3 months Resolved/3 months
Cone et al., 200434 C. tropicalis Vertebra M/76 y Back pain DM, CABG earlier, AB LF AmB 5 mg/kg/day IV 6 weeks Resolved/2 months
Cone et al., 200434 C. glabrata Vertebra M/73 y Back pain Laparotomy, pneumonia,
fungemia (C. albicans,
C. glabrata), AB
LF AmB 5 mg/kg/day IV 18 days Resolved/unreported
Arias et al., 20045 C. albicans Talus F/66 y Pain, swelling;
BC positive
Multiple surgeries on right
ankle, multiple biopsies
positive for C. albicans
Surgery, ﬂuconazole 200 mg/day IV 8 weeks
and 200 mg/day PO 12 months
Resolved/12 months
Lerch et al., 200335 C. albicans Tibia,
femur
F/78 y Pain, fever,
swelling
AB, sepsis earlier, knee
alloplasty
Fluconazole 400 mg/day 10 days, then
surgery, ﬂuconazole 800 mg/day 2 months
Resolved/2 months
Garbino et al., 200336 C. albicans Vertebra F/76 y Back pain,
radiating pain;
BC positive
Peritonitis, pneumonia, AB,
fungemia (C. albicans), CVC
AmB 0.5 mg/kg/day IV 2 weeks, ﬂuconazole
400 mg/day PO/(NA)
Clinical improvement/
6 months
Garbino et al., 200336 C. albicans Vertebra F/21 y Back pain,
radiating pain;
BC negative
IV drug abuse, hepatitis C Surgery, ﬂuconazole 400 mg/day PO 3 months,
relapse, ﬂuconazole 400 mg/day PO 6 months
Resolved clinically, MRI:
sequel lesions/13 months
Garbino et al., 200336 C. tropicalis Vertebra M/43 y Back pain;
BC negative,
CSF positive
Leukemia, chemotherapy Surgery, ﬂuconazole 800 mg/day IV 3 months,
itraconazole 600 mg/day PO (no time reported)
Resolved clinically, MRI
4 months later with
improvement/7 months
Seravalli et al., 200337 C. glabrata Vertebra M/64 y Back pain Surgery, DM Surgery, ﬂuconazole 800 mg/day IV 3 weeks,
AmB-d 10 weeks then LF AmB IV 8 weeks and
corpectomy because of instability
Clinical improvement,
radiology without changes,
side effects (elevated
transaminases and
nephrotoxicity) led to LF
AmB; resolved/16 months
El-Zaatari et al., 200238 C. albicans Vertebra M/65 y Back pain,
malaise; BC
negative
IDDM Fluconazole 2 weeks preoperatively, surgery Resolved
Oliverson et al., 200239 C. parapsilosis Tibia M/34 y Wound infection Open fracture, IV AB Surgery, AmB cement beads in non-union
fracture; ﬂuconazole PO 2 months,
bone grafting
Resolved (X-ray) after
3 months
AAA, abdominal aortic aneurysm; AB, antibiotics; AmB, amphotericin B; AmB-d, amphotericin B deoxycholate; AML, acute myeloid leukemia; BC, blood culture; BMT, bone marrow transplantation; CABG, coronary artery bypass
grafting; CSF, cerebrospinal ﬂuid; CVC, central venous catheter; DM, diabetes mellitus; F, female; HIV, human immunodeﬁciency virus; IDDM, insulin-dependent diabetes mellitus; IO, intraosseous; IV, intravenous; LF AmB,
liposomal formulation of amphotericin B; m, months; M, male; MRI, magnetic resonance imaging; NA, not available; PO, per os (oral); SI-joint, sacroiliac joint; y, years.
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N.C. Kaldau et al. / International Journal of Infectious Diseases 16 (2012) e16–e22e20complete recovery. Seven patients (7%) died, three of them with
mediastinitis. In general, all of the patients who died had a non-
related disease as the cause of death, or the Candida osteomyelitis
was a part of an invasive candidiasis. A total of 24 patients (23%)
improved clinically and/or radiologically.
In 2005, Shaikh et al. reviewed the literature on osteomyelitis
caused by C. tropicalis and found 19 cases.31 Of the 19 patients, 15
(79%) recovered, and none of them were infected by more than one
Candida species.
5. Discussion
The described case is representative of a late diagnosis of Candida
osteomyelitis caused by low pathogenic microorganisms, with
limited symptoms and clinical ﬁndings. The patient was a middle-
aged man with an initially slow onset of illness dominated by mild
pain in one ankle and swelling of both ankles. The patient had several
risk factors: broad-spectrum antibiotic usage, CVC, abdominal
surgery, and candidemia. In this situation, the localization, the
leukocytoclastic vasculitis on both feet, and the initial antifungal
therapy probably all contributed to mask the symptoms and
diagnosis. Insufﬁcient surgical revisions could have contributed to
the delay in ﬁnal diagnosis because an early leukocyte scan
suggested bilateral bone involvement. Candida osteomyelitis should
be considered when a patient presents with risk factors and pain
without previous trauma, because Candida, despite being part of the
normal ﬂora, is the fourth leading cause of hematogenous
nosocomial infections.40,41 This case was unusual because of the
bilateral involvement. To our knowledge, this is only the ﬁfth
Candida osteomyelitis patient with involvement of the foot. Usually,
a single bone of a vertebra, a rib, or the sternum is the infectious
focus.5,17,27,42,43 Candida osteomyelitis of the foot is rarely seen, but
it is important to remember that it may occur. We identiﬁed only six
previously described cases in which polymicrobial osteomyelitis
was caused by two or more species of Candida.7–12 The few reported
cases of polymicrobial Candida osteomyelitis may be due to rarity or
diagnostic uncertainty. Underreporting may be the cause, but
because there have been at least 150 reported cases of Candida
osteomyelitis and only six of them were polymicrobial, we conclude
that osteomyelitis caused by two or more species of Candida is rare.
We identiﬁed only two cases of C. krusei osteomyelitis; therefore, the
present case represents a rarity among Candida osteomyelitis
cases.7,13 The clinical signiﬁcance of C. krusei is well documented,
especially in immunosuppressed patients.44
Prophylactic ﬂuconazole therapy has led to an increase in
resistant Candida species and a rise in non-albicans infections.6,45
This trend appears to also apply to osteomyelitis, in which C.
albicans accounted for 58% of cases until 2002, versus 51% after
2002, although it is not feasible to conduct a quantitative data
synthesis of outcomes reported in the case series because of the
risk of bias (Table 1).5
A total of 80% of patients from 2002 to 2010 achieved a full
recovery, compared to 62% before 2002. Whether this increase is
due to earlier diagnosis, a more appropriate treatment strategy
with surgery and drugs, or a more accurate treatment length
remains unclear. However, because we expect more cases of
Candida osteomyelitis with resistant strains due to an increase in
the population of patients with risk factors and the increased use of
prophylactic antifungal drugs, an improvement in outcome is
satisfying. It is also worth noting that in only two cases identiﬁed
since 2002 have side effects been reported, and only in one case
was treatment changed (Table 1). However, this may be a result of
underreporting.
There seems to be a trend toward C. albicans having a less
favorable outcome than other species, which could be related to
the rise in non-albicans species (Table 1).5Since the mid-1990s, ﬂuconazole has been established as one of
the main treatments for Candida osteomyelitis, either as mono-
therapy or in combination with AmB. However, there has been no
consensus on treatment length. The recent recommendation of the
Infectious Diseases Society of America (IDSA) is ﬂuconazole
400 mg/day for 6–12 months, or LF AmB 3–5 mg/kg/day for at
least 2 weeks, followed by ﬂuconazole 400 mg/day for 6–12
months.46 Alternatively, the use of an echinocandin or AmB 0.5–
1 mg/kg/day for at least 2 weeks, followed by ﬂuconazole 400 mg/
day for 6–12 months is a possibility.
The use of ﬂuconazole in invasive candidiasis has been shown to
have fewer side effects than AmB and has presented comparable
results in terms of symptom relief and mortality.47,48 Fluconazole
is attractive because it can be administered orally, thus reducing
hospital stay and treatment cost.
Until the introduction of ﬂuconazole, AmB was the ﬁrst-line
treatment for invasive candidiasis. However, due to nephrotoxici-
ty, various liposomal formulations of AmB with lower nephrotoxi-
city than AmB have been introduced.49 There have been few
reports of treatment of Candida osteomyelitis with LF AmB, but in
cases where these drugs have been used, good effects have been
reported, and we have been unable to identify reports of side
effects.18,30,32,34,37,50 In one case of relapse after treatment with LF
AmB, the patient achieved complete remission with ﬂuconazole.50
Because AmB is fungicidal whereas ﬂuconazole is fungistatic, it
makes sense to initially use LF AmB in the treatment of particularly
susceptible individuals or for more severe cases. Subsequently, oral
treatment with ﬂuconazole might be reduced. In cases where there
is resistance to ﬂuconazole or decreased sensitivity (as with C.
krusei), LF AmB could be used as monotherapy and treatment
length guided by clinical signs, WBC counts, CRP, MRI, and possible
side effects. Echinocandins, also fungicidal to Candida in vitro, are
slightly better than LF AmB in terms of nephrotoxicity, liver
enzyme changes, and general side effects, including fever, chills,
nausea, vomiting, and dyspnea.49 Therefore, it may seem rational
to use an echinocandin as an alternative to LF AmB, as
recommended by the IDSA. Five cases of treatment with
caspofungin have been described (Table 1). Two cases were
treated with monotherapy with good results.24,26 One patient
received medical treatment 6 weeks after surgery. Two cases were
successfully treated with surgery and subsequent caspofungin and
an azole.13,27 Caspofungin was administered for 40 and 240 days,
followed by prolonged azole treatment. In one case, treatment
with caspofungin led to relapse, but this was a case of a prolonged
multi-pharmacological treatment of C. dubliniensis in a stem cell
transplant patient.16 Subsequently, the patient was successfully
treated with caspofungin and voriconazole. There is a need for
further research on the appropriate length of treatment with
echinocandins.
It has been recommended that vascular catheters be removed
and that the focus of infection be revised prior to antifungal
treatment.51,52 Especially in cases with spinal involvement,
malignancy may be a differential diagnosis, and a needle biopsy
may precede surgery.53
6. Conclusions
The number of non-albicans Candida infections is increasing,
and this review reports an increase in the number of cases of non-
albicans osteomyelitis. A rare case of bilateral polymicrobial
osteomyelitis of the feet with C. krusei and C. tropicalis is discussed.
C. albicans is still the most common Candida species in Candida
osteomyelitis. The condition is predominantly diagnosed in men,
and the axial skeleton is primarily affected. Candida osteomyelitis
should be considered when a patient presents with risk factors and
pain without previous trauma, because Candida, despite being part
N.C. Kaldau et al. / International Journal of Infectious Diseases 16 (2012) e16–e22 e21of the normal ﬂora, is the fourth leading cause of hematogenous
nosocomial infections. The treatment results are excellent, with
complete remission in most patients. Treatment in recent years has
primarily been surgery followed by ﬂuconazole as monotherapy, or a
combination of ﬂuconazole and initial treatment with a fungicidal
agent, either amphotericin B deoxycholate, a liposomal formulationAppendix A
Listed in the Table below are our comments on the review by Arias
Arias review mentioned in the section ‘‘Literature review’’.
Comments on Arias et al., 2004. Candida albicans osteomyelitis: 
Reference Arias et al. (Species, localization, treatment, outco
Marra et al., 200154 One case of C. albicans, femur, ﬂuconazole, improve
Heald et al., 200143 Three cases of C. albicans, foot, AmB, improvemen
Petrikkos et al., 20017 One case of C. albicans, sternum, ﬂuconazole,
improvement; one case of C. krusei, sternum,
itraconazole, improvement
Hendrickx et al., 200155 Three cases of C. albicans, one case of C. glabrata, and
cases of C. tropicalis; vertebral, ﬂuconazole and Am
improvement
Williams et al., 199956 Three cases of C. albicans, vertebra, only surgical
treatment, outcome NA
Turner et al., 199950 One case of C. albicans, spine, AmB, relapse 
McCullers and Flynn 199857 One case of C. tropicalis, femur, AmB, resolved 
Belzunegui et al., 199758 Two cases of C. albicans; location, treatment, and
outcome NA
Flanagan and Barnes 199759 Three cases of C. albicans, location NA, ﬂuconazole
complications
Munk et al., 199760 One case of C. albicans, spine, AmB, improvement 
Arranz-Caso et al., 19969 One case of C. albicans, zygomatic bone, AmB,
improvement
Ferra et al., 199461 One case of C. tropicalis, vertebra, AmB, died 
Ashman and
Papadimitriou 199162
One case of C. albicans, inner ear; treatment and outc
NA
Quindos et al., 199063 One case of C. albicans, spine 
Sugar et al., 199011 Two cases, species NA, costochondral and vertebra
ﬂuconazole, resolved
Neale et al., 198764 One case of C. albicans, vertebra, AmB, improveme
Bruns et al., 198612,65 One case of C. glabrata and C. tropicalis, spine, AmB
ﬂucytosine, resolved
Pohjola-Sintonen et al., 198466 One case of C. albicans, spine, AmB and ﬂucytosine
relapsed
Gustke and Wu 198167 One case of C. glabrata, location NA, AmB, resolved
Brill et al., 197968 Four cases of C. albicans, long bones, iliac bone, cla
and spine; treatment NA, healed, two with sequel
Svirsky-Fein et al., 197969 Two cases of C. tropicalis; location, treatment, and
outcome NA
AmB, amphotericin B; NA, not available.of AmB, or echinocandins. Treatment experience with the liposomal
formulation of AmB and echinocandins is limited, but promising
results have been reported. The optimal treatment duration remains
unclear and depends on the clinical assessment of each patient.
Conﬂict of interest: The authors have no conﬂict of interest to
declare. et al.5 Our comments are incorporated into the conclusions of the
case report and literature review
me) Comments
ment The Candida osteomyelitis was resolved, a secondary bacterial infection
t Only one case microbiologically veriﬁed
Both resolved
 two
B,
One patient with C. glabrata died, two patients with C. albicans were cured
after AmB and ﬂuconazole. One patient with C. albicans also needed
ﬂucytosine and itraconazole to resolve. One patient with C. tropicalis
improved after AmB and ﬂuconazole and one with C. tropicalis resolved
after AmB and ﬂuconazole treatment
Only two cases are veriﬁed; one due to C. albicans, the other type NA. One
improved after surgery only, and the other improved after AmB and
ﬂuconazole
Resolved after treatment with AmB and ﬂucytosine
Three cases of C. tropicalis. Of the two not mentioned, one was localized to
the femur and the humerus, which resolved on treatment with an azole,
and one was a metacarpal osteomyelitis in which the patient died after
treatment with AmB
Two cases of costal C. albicans resolved after ketoconazole
, Only one case of spinal osteomyelitis; the patient was also treated with
AmB and ﬂucytosine; died
Resolved
No effect of ﬂuconazole but resolved after AmB
Two cases of C. tropicalis; one of them resolved after AmB and ﬂucytosine,
the other died from invasive candidiasis
ome This paper is a mouse study, and has not been included in the chapter
‘‘Literature review’’
Three cases of vertebral osteomyelitis with C. pseudotropicalis, C.
paratropicalis, and C. parapsilosis, respectively, which all resolved after
AmB treatment
l, A costal C. albicans and a vertebral double infection with C. tropicalis and
C. paratropicalis; both recovered after ﬂuconazole treatment
nt Resolved
 and This case is mentioned twice due to a double publication in the English
and German literature
, After relapsing, the patient was treated with ketoconazole and resolved
 Location in the femur
vicle
ae
Only one case can be veriﬁed; it improved after treatment
Two cases of C. tropicalis in both humerus and femur; both recovered after
treatment with AmB and ﬂuconazoleReferences
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